Realtime nieuws over Johnson & Johnson (JNJ). Lees het hier

6 januari 2026 · Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study · Persbericht

30 december 2025 · Johnson & Johnson neemt Halda Therapeutics over voor 3 miljard dollar; nieuwe kankertherapieën op komst · Business AM

Key takeaways Johnson & Johnson heeft Halda Therapeutics overgenomen voor 3,05 dollar dollar (ongeveer 2,6 miljard euro) en versterkt daarmee zijn oncologiepijplijn met het innovatieve Regulated Induced Proximity Targeting...

18 december 2025 · Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma · Persbericht

18 december 2025 · U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib) · Persbericht

15 december 2025 · Johnson & Johnson krijgt boete van 40 miljoen dollar in zaak rond kankerverwekkend talkpoeder · Business AM

Key takeaways Twee Californische vrouwen krijgen een schadevergoeding van in totaal 40 miljoen dollar (34 miljoen euro) van Johnson & Johnson. De jury achtte het bedrijf verantwoordelijk voor de diagnose van hun eierstokkanker....

13 december 2025 · U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care* · Persbericht

9 december 2025 · Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma · Persbericht

6 december 2025 · Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma · Persbericht

5 december 2025 · Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC · Persbericht

3 december 2025 · Johnson & Johnson Teams Up with Naomi Watts to Reveal Why an Eye Exam is the Ultimate Self-Care Move for Women Over 40 · Persbericht

17 november 2025 · New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis · Persbericht

12 november 2025 · Beurzen verschuiven: Dow op record, tech onder druk · LYNX

Beursnieuws Amerika De Amerikaanse beurzen kenden dinsdag een opvallende rotatie tussen sectoren. Terwijl de Dow Jones Industrial Average met +1,18% steeg naar een nieuw record van 47.928 punten, verloor de Nasdaq Composite...

6 november 2025 · FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder · Persbericht

29 oktober 2025 · Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting · Persbericht

27 oktober 2025 · New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile · Persbericht

27 oktober 2025 · TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years · Persbericht

27 oktober 2025 · Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis · Persbericht

25 oktober 2025 · Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies · Persbericht

24 oktober 2025 · Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis · Persbericht

19 oktober 2025 · Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer · Persbericht

Johnson & Johnson JNJ

6 januari 2026 · Johnson & Johnson unveils new data showing nipocalimab is the first and only investigational FcRn blocker with potential to reduce systemic lupus erythematosus (SLE) activity in a Phase 2 study · Persbericht

30 december 2025 · Johnson & Johnson neemt Halda Therapeutics over voor 3 miljard dollar; nieuwe kankertherapieën op komst · Business AM

18 december 2025 · Johnson & Johnson Receives FDA Approval for TRUFILL n‑BCA Liquid Embolic System for the Treatment of Symptomatic Chronic Subdural Hematoma · Persbericht

18 december 2025 · U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib) · Persbericht

15 december 2025 · Johnson & Johnson krijgt boete van 40 miljoen dollar in zaak rond kankerverwekkend talkpoeder · Business AM

13 december 2025 · U.S. FDA approves AKEEGA® as the first precision therapy for BRCA2-mutated metastatic castration-sensitive prostate cancer with 54% reduction in disease progression vs standard of care* · Persbericht

9 december 2025 · Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma · Persbericht

6 december 2025 · Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma · Persbericht

5 december 2025 · Johnson & Johnson's INLEXZO™ (gemcitabine intravesical system) delivers 74 percent disease-free survival at one year in BCG-unresponsive, high-risk, papillary-only NMIBC · Persbericht

3 december 2025 · Johnson & Johnson Teams Up with Naomi Watts to Reveal Why an Eye Exam is the Ultimate Self-Care Move for Women Over 40 · Persbericht

17 november 2025 · New long-term data reinforces TREMFYA® (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis · Persbericht

12 november 2025 · Beurzen verschuiven: Dow op record, tech onder druk · LYNX

6 november 2025 · FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder · Persbericht

29 oktober 2025 · Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting · Persbericht

27 oktober 2025 · New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile · Persbericht

27 oktober 2025 · TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years · Persbericht

27 oktober 2025 · Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis · Persbericht

25 oktober 2025 · Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies · Persbericht

24 oktober 2025 · Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis · Persbericht

19 oktober 2025 · Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer · Persbericht

Mijn selecties